Thymagen

Thymagen is commonly used as a transliteration or market synonym for Thymogen/Oglufanide, the Glu-Trp dipeptide. The evidence base includes older clinical or comparative studies, mechanistic immune research, and review literature. PubMed-indexed work reported effects of thymagen, thymalin, and vilosen on cyclic nucleotide metabolism in sensitization and anaphylactic-shock models. A small older clinical study evaluated Thymogen in type 1 diabetes patients with secondary immunodeficiency, but it is not enough for broad immune or metabolic treatment claims. A modern THP-1 monocyte/macrophage study included Thymogen among Khavinson peptide preparations affecting proliferative and inflammatory pathways.

Immune-Cell Signaling

Thymagen, thymalin, and vilosen were studied for effects on cAMP/cGMP levels and phosphodiesterase activity in spleen lymphocytes under sensitization and anaphylactic-shock conditions ^[1].

Older Clinical Context

Thymogen was evaluated in type 1 diabetes patients with secondary immunodeficiency, but this small older study is not definitive ^[2].

Inflammation Models

Thymogen was included in a THP-1 monocyte/macrophage study of proliferative activity and inflammatory pathways ^[3].

Limited Human Evidence

Thymagen/Thymogen should not be presented as proven immune enhancement, diabetes, infection, or anti-aging therapy based on the cleared literature ^[2][4].

Immunomodulation Caution

Human dosing, long-term safety, immunogenicity, pregnancy safety, autoimmune risk, and interaction profiles are not adequately established by modern trials ^[2][4].